Current Editions

As data on amyloid-targeting drugs have emerged, pressing questions—and answers—about their leading safety concern have come into focus

Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex

Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia

Dual GIP/GLP-1 agonist shows highly competitive efficacy, safety, dosing flexibility; although oral dose could limit commercial supply

BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo

Deal-making with the West offers a path through uncertain times, but in what position will China biotechs emerge from the bear?

Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products

Panels to discuss Andexxa’s full approval, medical devices that use generative AI, and the REMS for clozapine

Six papers detail improved ways to degrade cell-surface cancer proteins through the lysosome

BioCentury’s roundup of translational innovations also includes a study from Amgen and a newco spotlight

Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ

M&A and licensing deals feature prominently in nearly all categories of this year’s BayHelix Awards

In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week